Literature DB >> 22245039

Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction.

Christian Jung1, Peder Sörensson, Nawsad Saleh, Håkan Arheden, Lars Rydén, John Pernow.   

Abstract

OBJECTIVES: Microparticles (MP) are small membrane vesicles, released from activated, damaged and apoptotic endothelial cells (EMP) or platelets (PMP) that may actively modulate inflammation, coagulation and vascular function. We tested the hypothesis that the number of circulating EMP or PMP in acute myocardial infarction correlates with the myocardium at risk (MaR) and infarct size (IS).
METHODS: EMP were quantified in plasma samples of 36 patients (age: 63±10 years) with first time ST-elevation myocardial infarction (STEMI) using flow cytometry. EMP were defined as CD31(+)/CD42(-) MP and CD144(+) MP and PMP as CD31(+)/CD42(+) MP. MaR and IS was determined by cardiovascular magnetic resonance imaging one week after the index event.
RESULTS: Plasma levels of CD31(+)/CD42(-) EMP were 251.0±178.8/μl and CD144(+) 106.3±33.7/μl. PMP levels were 579.2±631.8/μl. MaR was 31.0±11.2% of the left ventricle and IS was 11.4±7.1% of the left ventricle. Patients with STEMI in the left anterior descending artery had higher levels of CD31(+)/CD42(-) EMP and PMP than those with other infarct-related arteries (p<0.05). The numbers of CD31(+)/CD42(-) EMP and PMP correlated to MaR, but not to IS.
CONCLUSIONS: Circulating EMP and PMP correlate to the size of MaR in patients with STEMI suggesting that they reflect the severity of the endothelial injury and platelet activation during myocardial ischemia. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22245039     DOI: 10.1016/j.atherosclerosis.2011.12.025

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  37 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 2.  Microparticles and cardiovascular diseases.

Authors:  Christos Voukalis; Eduard Shantsila; Gregory Y H Lip
Journal:  Ann Med       Date:  2019-06-17       Impact factor: 4.709

3.  [Assessment of microcirculation in critically ill patients].

Authors:  C Jung; M Kelm; M Ferrari
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-09       Impact factor: 0.840

4.  Flow analysis of individual blood extracellular vesicles in acute coronary syndrome.

Authors:  Murad Vagida; Anush Arakelyan; Anna Lebedeva; Jean-Charles Grivel; Alexander Shpektor; Elena Vasilieva; Leonid Margolis
Journal:  Platelets       Date:  2016-09-05       Impact factor: 3.862

5.  Analysis of Extracellular Vesicles Using Magnetic Nanoparticles in Blood of Patients with Acute Coronary Syndrome.

Authors:  M S Vagida; A Arakelyan; A M Lebedeva; J-Ch Grivel; A V Shpektor; E Yu Vasilieva; L B Margolis
Journal:  Biochemistry (Mosc)       Date:  2016-04       Impact factor: 2.487

6.  Whether Circulating miRNAs or miRNA-Carriers Serve as Biomarkers for Acute Myocardial Infarction.

Authors:  Hongyan Zhu; Guo-Chang Fan
Journal:  J Biomark Drug Dev       Date:  2012-08-02

Review 7.  COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease.

Authors:  Che Mohd Nasril Che Mohd Nassir; Sabarisah Hashim; Kah Keng Wong; Sanihah Abdul Halim; Nur Suhaila Idris; Nanthini Jayabalan; Dazhi Guo; Muzaimi Mustapha
Journal:  Mol Neurobiol       Date:  2021-06-26       Impact factor: 5.590

8.  Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study.

Authors:  Daniel Kretzschmar; Christian Jung; Sylvia Otto; Stephan Utschig; Michael Hartmann; Thomas Lehmann; Atilla Yilmaz; Tudor C Pörner; Hans R Figulla; Markus Ferrari
Journal:  Cardiovasc Ultrasound       Date:  2012-05-21       Impact factor: 2.062

9.  Microvesicles: novel biomarkers for neurological disorders.

Authors:  Elisa Colombo; Bruno Borgiani; Claudia Verderio; Roberto Furlan
Journal:  Front Physiol       Date:  2012-03-29       Impact factor: 4.566

Review 10.  The role of microparticles in chronic obstructive pulmonary disease.

Authors:  Toru Takahashi; Hiroshi Kubo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.